CoChat

Repeat vaccination reduces antibody affinity maturation across different influenza vaccine platforms in humans

Open access

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Abstract

Several vaccines are approved in the United States for seasonal influenza vaccination every year. Here we compare the impact of repeat influenza vaccination on hemagglutination inhibition (HI) titers, antibody binding and affinity maturation to individual hemagglutinin (HA) domains, HA1 and HA2, across vaccine platforms. Fold change in HI and antibody binding to HA1 trends higher for H1N1pdm09 and H3N2 but not against B strains in groups vaccinated with FluBlok compared with FluCelvax and Fluzone. Antibody-affinity maturation occurs against HA1 domain of H1N1pdm09, H3N2 and B following vaccination with all vaccine platforms, but not against H1N1pdm09-HA2. Importantly, prior year vaccination of subjects receiving repeat vaccinations demonstrated reduced antibody-affinity maturation to HA1 of all three influenza virus strains irrespective of the vaccine platform. This study identifies an important impact of repeat vaccination on antibody-affinity maturation following vaccination, which may contribute to lower vaccine effectiveness of seasonal influenza vaccines in humans.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-019-11296-5

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 HI titers following vaccination with FluBlok, FluCelvax, and Fluzone. a–f Average HI titers against H1N1pdm09 (a, d), H3N2 (b, e), and influenza B (c, f) virus strains pre-vaccination (D0) and post-vaccination (D28) are shown for FluBlok, FluCelvax, and Fluzone (excluding repeat vaccinators, see Table 2), in the first (2015–2016) year (a–c) and second (2016–2017) year of the study (d–f). The box and whisker plot show the median value and the minimum and maximum values. For the Day 28 post-vaccination HI titers and fold change from Day 0, an ANCOVA model was used for comparison between the vaccine groups, adjusted for gender, age, and baseline (Day 0) values (Supplementary Tables 2 and 3). Statistically significant differences between groups and pairs are indicated by horizontal bars. Source data are provided as a Source Data file
Fig. 1 HI titers following vaccination with FluBlok, FluCelvax, and Fluzone. a–f Average HI titers against H1N1pdm09 (a, d), H3N2 (b, e), and influenza B (c, f) virus strains pre-vaccination (D0) and post-vaccination (D28) are shown for FluBlok, FluCelvax, and Fluzone (excluding repeat vaccinators, see Table 2), in the first (2015–2016) year (a–c) and second (2016–2017) year of the study (d–f). The box and whisker plot show the median value and the minimum and maximum values. For the Day 28 post-vaccination HI titers and fold change from Day 0, an ANCOVA model was used for comparison between the vaccine groups, adjusted for gender, age, and baseline (Day 0) values (Supplementary Tables 2 and 3). Statistically significant differences between groups and pairs are indicated by horizontal bars. Source data are provided as a Source Data fileCC BY · PubMed Central
Fig. 2 Post-vaccination sera binding to native HA0, HA1, and HA2 domains. a–j Steady-state equilibrium analysis of human vaccine sera pre-vaccination (D0) and post-vaccination (D28) against properly folded homologous H1N1pdm09 HA0 (a, f), HA1 (b, g), and HA2 (c, h) domains, and H3N2 HA1 (d, i), and B-HA1 (e, j) are measured using SPR. Recombinant HA0, HA1, and HA2 domains are immobilized on a sensor chip through the free amine group. Binding of the polyclonal serum antibodies to the immobilized protein is shown as resonance unit (RU) values for individual subjects receiving FluBlok (in blue), FluCelvax (in red), and Fluzone (in green) for each subject (excluding repeat vaccinators) in year 1 (2015–2016; D0, D28, and D180; a–e) and year 2 (2016–2017; D0 and D28; f–j) of the study. For Day 28 post-vaccination resonance units (RU), and fold change from Day 0, an ANCOVA model was used for comparison between the vaccine groups, adjusted for gender, age, and baseline (Day 0) values (Supplementary Tables 4 and 5). Statistically significant differences between groups and pairs are indicated by horizontal bars. Source data are provided as a Source Data file
Fig. 2 Post-vaccination sera binding to native HA0, HA1, and HA2 domains. a–j Steady-state equilibrium analysis of human vaccine sera pre-vaccination (D0) and post-vaccination (D28) against properly folded homologous H1N1pdm09 HA0 (a, f), HA1 (b, g), and HA2 (c, h) domains, and H3N2 HA1 (d, i), and B-HA1 (e, j) are measured using SPR. Recombinant HA0, HA1, and HA2 domains are immobilized on a sensor chip through the free amine group. Binding of the polyclonal serum antibodies to the immobilized protein is shown as resonance unit (RU) values for individual subjects receiving FluBlok (in blue), FluCelvax (in red), and Fluzone (in green) for each subject (excluding repeat vaccinators) in year 1 (2015–2016; D0, D28, and D180; a–e) and year 2 (2016–2017; D0 and D28; f–j) of the study. For Day 28 post-vaccination resonance units (RU), and fold change from Day 0, an ANCOVA model was used for comparison between the vaccine groups, adjusted for gender, age, and baseline (Day 0) values (Supplementary Tables 4 and 5). Statistically significant differences between groups and pairs are indicated by horizontal bars. Source data are provided as a Source Data fileCC BY · PubMed Central
Fig. 3 Kinetics of antibody affinity maturation following human vaccination. a–j Sequential SPR analysis of human vaccine sera (pre- and post- vaccination) was performed against properly folded homologous H1N1pdm09 HA0 (a, f), HA1 (b, g), and HA2 (c, h) domains, and H3 HA1 (d, i) and B-HA1 (e, j). Samples from 16 individuals (Table 2) that received repeat vaccination in both year 1 and year 2 (Fig. 4) are not included in the Fig. 3 dataset. Ten-fold, 50- and/or 250-fold diluted individual serum from each participant in the vaccine study at pre-vaccination (D0) and at 28 days or 180 days after immunization (D28, D180) are evaluated as shown for FluBlok (in blue), FluCelvax (in red), and Fluzone (in green) for subjects recruited in the first year (2015–2016; a–e) and second year (2016–2017; D0 and D28; f–j). Serum antibody off-rate constants are determined as described in Methods. Slower dissociation kinetics (off-rate) of antigen–antibody complex means higher antibody affinity. For Day 28 post-vaccination off-rate constants, and fold change from Day 0, an ANCOVA model was used for comparison between the vaccine groups, adjusted for gender, age, and baseline (Day 0) values (Supplementary Tables 6 and 7). Statistically significant differences between groups and pairs are indicated by horizontal bars. Source data are provided as a Source Data file
Fig. 3 Kinetics of antibody affinity maturation following human vaccination. a–j Sequential SPR analysis of human vaccine sera (pre- and post- vaccination) was performed against properly folded homologous H1N1pdm09 HA0 (a, f), HA1 (b, g), and HA2 (c, h) domains, and H3 HA1 (d, i) and B-HA1 (e, j). Samples from 16 individuals (Table 2) that received repeat vaccination in both year 1 and year 2 (Fig. 4) are not included in the Fig. 3 dataset. Ten-fold, 50- and/or 250-fold diluted individual serum from each participant in the vaccine study at pre-vaccination (D0) and at 28 days or 180 days after immunization (D28, D180) are evaluated as shown for FluBlok (in blue), FluCelvax (in red), and Fluzone (in green) for subjects recruited in the first year (2015–2016; a–e) and second year (2016–2017; D0 and D28; f–j). Serum antibody off-rate constants are determined as described in Methods. Slower dissociation kinetics (off-rate) of antigen–antibody complex means higher antibody affinity. For Day 28 post-vaccination off-rate constants, and fold change from Day 0, an ANCOVA model was used for comparison between the vaccine groups, adjusted for gender, age, and baseline (Day 0) values (Supplementary Tables 6 and 7). Statistically significant differences between groups and pairs are indicated by horizontal bars. Source data are provided as a Source Data fileCC BY · PubMed Central
Fig. 4 Impact of repeat vaccination on HI titers and antibody affinity maturation. a–c Fold change in end-point titers are calculated by dividing post-vaccination (D28) titers by pre-vaccination (D0) titers of respective years for HI against H1N1pdm09 (a), H3N2 (b), and influenza B (c) virus strains as shown for FluBlok (in blue), FluCelvax (in red), and Fluzone (in green) for each of the 16 repeatedly vaccinated individuals. d–k Sequential SPR analysis of human vaccine sera (pre- and post- vaccination) was performed against properly folded H1N1pdm09 HA1 (d) and HA2 (e) domains, and H3 HA1 (f) and B-HA1 (g). Ten-fold, 50- and/or 250-fold diluted individual serum from 16 repeatedly vaccinated participants at pre-vaccination (D0) and post-vaccination (D28; D180 for year 1 only) are evaluated as shown for FluBlok (in blue), FluCelvax (in red), and Fluzone (in green) for each subject in the first year (2015–2016; S1) and second year (2016–2017; S2). Serum antibody off-rate constants are determined as described in Methods. h–k Fold increase in antibody affinity was calculated [1/(off-rate on Day 28/off-rate on Day 0)] for respective years against H1N1pdm09 HA1 (h) and HA2 (i) domains, H3N2 HA1 (j) and B-HA1 (k). Source data are provided as a Source Data file
Fig. 4 Impact of repeat vaccination on HI titers and antibody affinity maturation. a–c Fold change in end-point titers are calculated by dividing post-vaccination (D28) titers by pre-vaccination (D0) titers of respective years for HI against H1N1pdm09 (a), H3N2 (b), and influenza B (c) virus strains as shown for FluBlok (in blue), FluCelvax (in red), and Fluzone (in green) for each of the 16 repeatedly vaccinated individuals. d–k Sequential SPR analysis of human vaccine sera (pre- and post- vaccination) was performed against properly folded H1N1pdm09 HA1 (d) and HA2 (e) domains, and H3 HA1 (f) and B-HA1 (g). Ten-fold, 50- and/or 250-fold diluted individual serum from 16 repeatedly vaccinated participants at pre-vaccination (D0) and post-vaccination (D28; D180 for year 1 only) are evaluated as shown for FluBlok (in blue), FluCelvax (in red), and Fluzone (in green) for each subject in the first year (2015–2016; S1) and second year (2016–2017; S2). Serum antibody off-rate constants are determined as described in Methods. h–k Fold increase in antibody affinity was calculated [1/(off-rate on Day 28/off-rate on Day 0)] for respective years against H1N1pdm09 HA1 (h) and HA2 (i) domains, H3N2 HA1 (j) and B-HA1 (k). Source data are provided as a Source Data fileCC BY · PubMed Central
Fig. 5 Impact of prior vaccination on HI and antibody affinity maturation. In the current study 38/69 individuals received inactivated seasonal influenza vaccine in the previous year (labeled inactivated), while 23/69 were not vaccinated with influenza vaccine in the previous year (labeled none). a–c End-point HI titers against H1N1pdm09 (a), H3N2 (b), and B (c) virus strains at Day 0 (D0; pre-vaccination) and Day 28 (D28; post-vaccination) are shown for FluBlok (in blue), FluCelvax (in red), and Fluzone (in green) for each subject. Fold change in end-point titers are calculated by dividing post-vaccination (Day 28) titers by pre-vaccination (Day 0) for individuals with prior vaccination (Inactivated; closed symbols) vs. no prior year vaccination (None; open symbols), and are shown for each vaccine group. d–k Sequential SPR analysis of human vaccine sera (pre- and post- vaccination) was performed against properly folded H1N1pdm09 HA1 (d) and HA2 (e) domains, H3N2 HA1 (f), and B-HA1 (g). Ten-fold, 50- and/or 250-fold diluted individual serum at pre-vaccination (D0) and at 28 days after immunization (D28) are evaluated for FluBlok (in blue), FluCelvax (in red), and Fluzone (in green) vaccinated individuals who received inactivated seasonal influenza vaccine in the previous year (Inactivated) and individuals who were not vaccinated with influenza vaccine in the previous year (None). Serum antibody off-rate constants are determined as described in Methods. h–k Increase in antibody affinity as measured by fold change in antigen–antibody complex dissociation rates was calculated [1/(off-rate on Day 28/off-rate on Day 0)] against H1N1pdm09 HA1 (h) and HA2 (i) domains, H3N2 HA1 (j) and B-HA1 (k) are shown for FluBlok (in blue), FluCelvax (in red), and Fluzone (in green) for each subject. Geometric means with 95% confidence intervals are shown. For pairwise comparison, an ANCOVA model was used for comparison between the vaccine groups, adjusted for gender, age, and baseline (Day 0) values (Supplementary Tables 8 and 9). Statistically significant differences between groups and pairs are indicated by horizontal bars. Source data are provided as a Source Data file
Fig. 5 Impact of prior vaccination on HI and antibody affinity maturation. In the current study 38/69 individuals received inactivated seasonal influenza vaccine in the previous year (labeled inactivated), while 23/69 were not vaccinated with influenza vaccine in the previous year (labeled none). a–c End-point HI titers against H1N1pdm09 (a), H3N2 (b), and B (c) virus strains at Day 0 (D0; pre-vaccination) and Day 28 (D28; post-vaccination) are shown for FluBlok (in blue), FluCelvax (in red), and Fluzone (in green) for each subject. Fold change in end-point titers are calculated by dividing post-vaccination (Day 28) titers by pre-vaccination (Day 0) for individuals with prior vaccination (Inactivated; closed symbols) vs. no prior year vaccination (None; open symbols), and are shown for each vaccine group. d–k Sequential SPR analysis of human vaccine sera (pre- and post- vaccination) was performed against properly folded H1N1pdm09 HA1 (d) and HA2 (e) domains, H3N2 HA1 (f), and B-HA1 (g). Ten-fold, 50- and/or 250-fold diluted individual serum at pre-vaccination (D0) and at 28 days after immunization (D28) are evaluated for FluBlok (in blue), FluCelvax (in red), and Fluzone (in green) vaccinated individuals who received inactivated seasonal influenza vaccine in the previous year (Inactivated) and individuals who were not vaccinated with influenza vaccine in the previous year (None). Serum antibody off-rate constants are determined as described in Methods. h–k Increase in antibody affinity as measured by fold change in antigen–antibody complex dissociation rates was calculated [1/(off-rate on Day 28/off-rate on Day 0)] against H1N1pdm09 HA1 (h) and HA2 (i) domains, H3N2 HA1 (j) and B-HA1 (k) are shown for FluBlok (in blue), FluCelvax (in red), and Fluzone (in green) for each subject. Geometric means with 95% confidence intervals are shown. For pairwise comparison, an ANCOVA model was used for comparison between the vaccine groups, adjusted for gender, age, and baseline (Day 0) values (Supplementary Tables 8 and 9). Statistically significant differences between groups and pairs are indicated by horizontal bars. Source data are provided as a Source Data fileCC BY · PubMed Central
Fig. 6 Prior year vaccination negatively impacts affinity maturation of antibodies. a–d Sequential SPR analysis of human influenza vaccine sera (pre- and post-vaccination) was performed against H1N1pdm09 HA1 (a) and HA2 (b) domains, H3N2 HA1 (c), and B-HA1 (d). Ten-fold, 50- and/or 250-fold diluted individual serum at pre-vaccination and following vaccination with FluBlok, FluCelvax, or Fluzone from individuals who received inactivated seasonal influenza vaccine in prior year (Inactivated) and individuals who were not vaccinated with influenza vaccine in the previous year (None). Serum antibody off-rate constants were determined as described in Methods. Increase in serum antibody affinity as measured by fold change in antigen–antibody complex dissociation rates was calculated as described in Fig. 5 [1/(off-rate on Day 28/off-rate on Day 0)] against H1N1pdm09 HA1 (a) and HA2 (b) domains, H3N2 HA1 (c) and B-HA1 (d) for each subject. Geometric means with 95% confidence intervals are shown. The pairwise comparison was analyzed using the Mann–Whitney non-parametric method between two groups. The significance between groups that are statistically significant with a p value of <0.005 (**) are shown. Source data are provided as a Source Data file
Fig. 6 Prior year vaccination negatively impacts affinity maturation of antibodies. a–d Sequential SPR analysis of human influenza vaccine sera (pre- and post-vaccination) was performed against H1N1pdm09 HA1 (a) and HA2 (b) domains, H3N2 HA1 (c), and B-HA1 (d). Ten-fold, 50- and/or 250-fold diluted individual serum at pre-vaccination and following vaccination with FluBlok, FluCelvax, or Fluzone from individuals who received inactivated seasonal influenza vaccine in prior year (Inactivated) and individuals who were not vaccinated with influenza vaccine in the previous year (None). Serum antibody off-rate constants were determined as described in Methods. Increase in serum antibody affinity as measured by fold change in antigen–antibody complex dissociation rates was calculated as described in Fig. 5 [1/(off-rate on Day 28/off-rate on Day 0)] against H1N1pdm09 HA1 (a) and HA2 (b) domains, H3N2 HA1 (c) and B-HA1 (d) for each subject. Geometric means with 95% confidence intervals are shown. The pairwise comparison was analyzed using the Mann–Whitney non-parametric method between two groups. The significance between groups that are statistically significant with a p value of <0.005 (**) are shown. Source data are provided as a Source Data fileCC BY · PubMed Central
Fig. 7 Correlations between fold change of HI and anti-HA1 antibody off-rates. a–e HI fold changes of all study participants are correlated with their change of antibody-binding off-rates against (a) H1N1pdm09 HA0; (b) H1N1pdm09 HA1; (c) H1N1pdm09 HA2; (d) H3 HA1; (e) B-HA1. Spearman correlations, assuming non-parametric correlation, are reported for the calculation of correlations between off-rate fold changes and HI fold changes across all vaccine groups in year 1 and year 2. The correlation coefficient and p values are reported for each set of all groups Source data are provided as a Source Data file
Fig. 7 Correlations between fold change of HI and anti-HA1 antibody off-rates. a–e HI fold changes of all study participants are correlated with their change of antibody-binding off-rates against (a) H1N1pdm09 HA0; (b) H1N1pdm09 HA1; (c) H1N1pdm09 HA2; (d) H3 HA1; (e) B-HA1. Spearman correlations, assuming non-parametric correlation, are reported for the calculation of correlations between off-rate fold changes and HI fold changes across all vaccine groups in year 1 and year 2. The correlation coefficient and p values are reported for each set of all groups Source data are provided as a Source Data fileCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 51 references

Cited by

See all 102

Metadata

Authors
Khurana, S., Hahn, M., Coyle, E. M., King, L. R., Lin, T.-L., Treanor, J., Sant, A., & Golding, H.
Affiliations
  • Center for Biologics Evaluation and Research (US)
  • University of Rochester Medicine (US)
Corresponding author
Khurana, Surender
Venue
Nature Communications
Published
2019-07-26
Volume
10
Issue
1
Pages
3338-3338
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2966564986
Cited by
101
References
51
Citations by year
2026: 10 · 2025: 10 · 2024: 12 · 2023: 14 · 2022: 19 · 2021: 19 · 2020: 11 · 2019: 5
FWCI
10.47
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (CEIRS Contract No. HHSN272201400005C)
Topics
  • Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
  • Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
Keywords
affinity maturation, hemagglutination inhibition, Fluzone, H1N1pdm09, H3N2, influenza B, vaccine effectiveness
MeSH terms
Adolescent, Adult, Antibodies, Viral, Antibody Affinity, Child, Child, Preschool, Female, Hemagglutination Inhibition Tests, Humans, Infant, Influenza, Human, Influenza Vaccines, Male, Middle Aged, Vaccination, Hemagglutinin Glycoproteins, Influenza Virus, Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Repeat vaccination reduces antibody affinity maturation across different influenza vaccine platforms in humans. https://app.cochat.ai/papers/10.1038/s41467-019-11296-5
The paper
Khurana, S., Hahn, M., Coyle, E. M., King, L. R., Lin, T.-L., Treanor, J., Sant, A., & Golding, H. (2019). Repeat vaccination reduces antibody affinity maturation across different influenza vaccine platforms in humans. Nature Communications. https://doi.org/10.1038/s41467-019-11296-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.